Date:1/26/2009

Three Months Ended ------------------ December 31, December 31, 2008 2007 ----------------- --------- As As Reported Adjustments Adjusted Reported -------- ----------- -------- -------- Service revenue $275,846 $275,846 $238,653 Reimbursement revenue 48,155 48,155 45,635 Total revenue 324,001 324,001 284,288 Costs and expenses: Direct costs 192,295 (15,000)(a) 177,295 156,991 Reimbursable out-of-pocket expenses 48,155 48,155 45,635 Selling, general and administrative 62,062 62,062 51,406 Depreciation 11,305 11,305 8,392 Amortization 2,474 2,474 1,382 Total costs and expenses 316,291 (15,000) 301,291 263,806 Income from operations 7,710 15,000 22,710 20,482 Other income (expense) 3,188 3,188 (329) Income before income taxes 10,898 15,000 25,898 20,153 Provision for income taxes 5,144 7,080(a) 12,224 8,326 Effective tax rate 47.2% 47.2% 41.3% Minority interest expense 546 546 296 Net income $5,208 $7,920 $13,128 $11,531 Earnings per common share: ------------------- B
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
2. PAREXEL Reports Preliminary Second Quarter Results
3. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
4. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
5. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
6. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
7. Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share
8. Quest Diagnostics Reports Growth in Revenue and Earnings for Fourth Quarter 2008 and Provides 2009 Guidance
9. Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter
10. MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
11. Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008